Brazilian organization documents opposition to Gilead’s antiretroviral patent application in India The Brazilian group Interdisciplinary AIDS Association, or ABIA, has joined Indian patient advocacy groups to oppose a patent application for Gilead Science’s antiretroviral medication Tenofovir, saying that the patent could have a direct effect on Brazil’s capability to produce and access affordable generic versions of the medication, India’s Business Regular reports. Opponents of the patent state that the drug includes a previously known substance and, therefore, can’t be patented under India’s Patents Work questions and answers .